Dr. Gomella on Immunotherapy Developments in Prostate Cancer

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy developments for patients with prostate cancer.

The customized immunotherapy that was approved almost 8 years ago, sipuleucel-T (Provenge), continues to be one of the mainstays of treatment for patients with advanced prostate cancer, says Gomella. Some institutional trials and other large national trials are looking at combining sipuleucel-T with other agents, such as enzalutamide (Xtandi).

An immuno-oncology drug with a novel antiandrogen treatment like enzalutamide may prove to be a benefit to patients with prostate cancer. Taking these advanced drugs and using them together in a long-term sequential fashion may prove to be beneficial, according to Gomella.